This is an HTML version of an attachment to the Freedom of Information request 'Documents regarding COVID 19 and the vaccination'.

Department Reference: FOI 3250 
Andria Vincekovic 
via email: 
Dear Ms Vincekovic 
I refer to your request of 23 October 2021 to the Department of Health (the 
department) seeking access under the Freedom of Information Act 1982 (Cth) (the FOI 
Act) to documents related to COVID-19. Your request is in the following terms: 
1.  Documentation proving isolation of the SARS COV2 Delta strain which is confirmed 
by means of a purified viral sample being imaged with an electron microscope. 
2.  Documentation where the isolated SARSCOV2 Delta virus sample mentioned in 
point (1) is exposed to healthy humans or animals and shown to cause the disease 
3.  Documentation where the COVID-19 vaccination has been proven to prevent 
individuals from contracting or spreading the disease COVID-19. 
4.  Documentation of the full list of ingredients as well as the adverse affects recorded 
from the COVID-19 vaccination since its introduction. 
Information about COVID-19 
SARS-CoV-2, the virus which causes COVID-19, is real. Multiple scientific studies 
across the world demonstrate that highly reputable laboratory medicine experts 
have isolated and sequenced the virus that causes COVID-19, demonstrating that the 
virus exists, that it exists in variant forms, that it is different from the influenza virus, 
and that it causes a disease that has resulted in over 5 million deaths worldwide in 
just over 22 months.  
While the department is not the custodian of the scientific studies establishing the 
existence of SARS-CoV-2, this research has informed the Australian Government’s 
response to the pandemic. You can find those scientific studies in the public domain. 
The department is a government agency and does not conduct scientific studies or 
laboratory testing for the SARS-CoV-2 in a laboratory. Diagnostic assays using 
reverse transcriptase polymerase chain reaction (RT-PCR) are conducted by testing 
laboratories throughout Australia. For more information, please see the Public 

Health Laboratory Network guidance on laboratory testing for SARS-CoV-2, which 
is available online:
In Australia, scientists at the Victorian Infectious Diseases Reference Laboratory at 
The Peter Doherty Institute for Infection and Immunity were the first to isolate 
SARS-CoV-2 outside of China, winning the 2020 MJA/MDA National Prize for 
Excellence in Medical Research. This critical information was immediately shared 
with local and overseas reference laboratories and major North American and 
European virus culture collections. These peer-reviewed, evidence-based 
publications provide scientific evidence for the existence of this deadly virus. 
All viruses, including SARS-CoV-2, change over time as part of their natural 
evolution. A change may or may not give the virus a biological advantage. Existing 
and emerging variants are constantly monitored using genomic surveillance to 
detect those that pose or may pose an increased risk to human health.  
In Australia, whole genome sequencing of the SARS-CoV-2 genome is the preferred 
way to determine the variant and mutation patterns of the virus, e.g. Alpha, Delta, 
and Kappa variants. Some RT-PCR tests have been designed to detect specific  
SARS-CoV-2 variants of concern. These tests can only identify the specific variants 
they have been designed for. 
Attached to this email is an article published in the Daily Telegraph on  
13 August 2021 that may be of interest to you. 
Information about COVID-19 Vaccines 
Before a prescription medicine (including a COVID-19 vaccine) can be legally 
supplied in Australia, the Therapeutics Goods Administration (TGA) rigorously 
assesses the safety, quality and effectiveness to determine if the benefits outweigh 
the risks. The risk-benefit approach assures consumers that the products they take 
are safe for their intended use, while still providing access to products that are 
essential to their health needs. More information can be found here: 
The TGA provisionally approved the Pfizer, AstraZeneca and Moderna COVID-19 
vaccine candidates after a complete assessment of all available data using the same 
process that is used for other vaccines approved in Australia. With rolling 
submission, collaboration with international regulators, and proactively working 
with sponsors, the evaluation of COVID-19 vaccines has been, and continues to be, 
expedited without compromising on strict standards of safety, quality and efficacy. 
The COVID-19 vaccines which have received provisional approval in Australia have 
each been shown to be highly effective in preventing severe illness, hospitalisation, 
and death from COVID-19, caused by SARS-CoV-2. The risk of a person infected 

with the SARS-CoV-2 virus developing symptomatic illness and becoming seriously 
unwell with COVID-19 is significantly reduced if that person has received a 
COVID-19 vaccine. For each provisionally approved vaccine, the TGA has 
established the acceptable safety, quality and efficacy of the vaccine based on a 
comprehensive evaluation of a wide range of information.  
Further information relating to the safety and efficacy of the COVID-19 vaccines 
available in Australia, including the Pfizer, AstraZeneca and Moderna vaccine 
candidates, is publicly available on the TGA website: 
Information about reported adverse events following vaccination 
The Therapeutic Goods Administration (TGA) maintains a Database of Adverse 
Event Notifications (DAEN) of reports of adverse events following the use of 
medicines in Australia, including the COVID-19 vaccines. The fact that an adverse 
event is reported on the DAEN following administration of a medicine does not 
mean the adverse event was related to the medicine. There might be no relationship 
between the adverse event and the medicine or vaccine – it may be a coincidence 
that the adverse event occurred when the medicine or vaccine was taken, and the 
symptom may be related to the underlying illness or to other factors.  
Expert analysis and review of adverse event reports is needed to determine whether 
there may be a link between reported event and the use of a medicine, such as a 
vaccination. The TGA analyses the data and reviews individual reports to identify 
possible safety issues for investigation. If these investigations confirm a safety signal, 
the TGA takes appropriate action. There is not a predefined number of adverse event 
reports that leads to removal of a product from the market because the type of action 
depends on the nature of the safety issue identified, including its likelihood and 
severity and the potential to mitigate the risk (such as through patient selection or 
monitoring), and the impact of the safety issue on the balance of benefits and risks 
for the product.  
The DAEN is available on the TGA website here: 
Information about vaccine ingredients 
A Product Information document (PI) provides a summary of the scientific 
information relevant to the safe and effective use of a prescription medicine, some 
non-prescription medicines and some biologicals. It provides objective information 
about the quality, safety and effectiveness of the medicine, as demonstrated in the 
data provided to the TGA by the pharmaceutical company. PI documents are written 
by the pharmaceutical company responsible for the medicine and must be approved 
by the TGA before publication.  

The PI includes information about adverse events observed in clinical trials and from 
post-market surveillance. The TGA works with pharmaceutical companies to ensure 
the PI remains up to date and can mandate updates to the safety information 
included in the PI.  
The PI documents, which include the ingredient lists for all vaccines available in 
Australia, can  be found online:
In addition, an Australian Public Assessment Report for prescription medicines 
(AusPAR) provides information about the evaluation of a prescription medicine and 
the considerations that led the TGA to approve or not approve an application. More 
information about AusPARs is available here:
Information about the vaccines that have provisional approval in Australia are 
available here:
FOI decision  
I am authorised under subsection 23(1) of the FOI Act to make decisions in relation 
to Freedom of Information requests. I am writing to notify you of my decision in 
response to your request.  
The FOI Act provides a mechanism for individuals to request access to documents 
held by relevant entities. It is not a mechanism for asking questions or seeking 
information that the entity does not hold in documents.  
Appropriate steps have been taken to find documents you have requested including 
consultation with relevant departmental officers and searches of departmental file 
management systems.  
I am satisfied, based on the consultation undertaken and the searches conducted, 
that the department, including the Therapeutic Goods Administration, does not hold 
any documents referred to in your request. This research and information is 
available in the public domain as described above. 
As a consequence, relying on section 24A of the FOI Act, I cannot provide access to 
the documents you requested. 

FOI review rights 
If you are dissatisfied with my decision, you may apply for a review. 
Internal review 
Under section 54 of the FOI Act, you may apply for internal review of this decision.  
In accordance with section 54B of the FOI Act, an application for internal review 
must be made in writing within 30 days after the day you are notified of this 
decision (or such further period as the department allows). To assist in the internal 
review process, please provide reasons you consider the review of my decision is 
The internal review will be carried out by another officer of this department within 
30 days of receipt of your application. 
An application for an internal review should be addressed to: 
Mail:   FOI Unit (MDP 516) 
Department of Health  
GPO Box 9848 
Information Commissioner review 
Alternatively, under section 54L of the FOI Act, you may apply to the Office of the 
Australian Information Commissioner (OAIC) for review of my decision by the 
Information Commissioner (IC).  
In accordance with subsection 54S(1) of the FOI Act, an IC review application in 
relation to a decision covered by subsection 54L(2) (access refusal decisions) must be 
made in writing within 60 days after the day you are notified of this decision (if you 
do not request an internal review). 
More information about IC review is available on the OAIC website at: 
The OAIC can be contacted by: 
Phone:  1300 363 992 
If you are dissatisfied with action taken by the department, you may also make a 

Complaint to the department 
Complaints to the department are covered by the department’s privacy policy. A 
form for lodging a complaint directly to the department is available on the 
department’s website:  
Complaint to the IC 
Information about making a complaint to the IC about action taken by the 
department is available on the OAIC website:
Relevant provisions of the FOI Act 
The FOI Act, including the provisions referred to in this letter, can be accessed from 
the Federal Register of Legislation website:  
If you require clarification of any of the matters discussed in this letter you should 
contact the department’s Freedom of Information Unit on (02) 6289 1666 or at  
Yours sincerely 
Megan Lancaster  
Assistant Secretary  
Public Health and Surveillance Branch 
22 November 2021